Sharpening our focus with critical feedback: Clinnova Advisory Board meeting and third Consortium meeting in Luxembourg

On 14 and 15 June, the Clinnova partners met in Belval, Luxembourg, for the third consortium meeting of the project. In addition, the Clinnova advisory board, comprised of six international experts on digital health and personalised medicine, joined on 14 June to hear about the latest status of the project and provide their critical feedback.


Over the day, the Clinnova partners presented the overall strategy of the project, and how Clinnova will drive the adoption of digital health and personalised medicine in Luxembourg. In further presentations, the topics dove deep into how research and innovation will play a role in the proposed Centre of Excellence, building on the existing strengths of Luxembourg in the areas of biomedical and data-driven research in order to provide value to patients, society and our other stakeholders.

The advisory board all agreed that Clinnova was a unique opportunity for Luxembourg and a worthy proposal for a TEAMING project, as the timing is perfect for digital health on a European landscape. However, it was clear that the consortium still has work to do, as the clock ticks towards the 15 November deadline. On the second day, the Clinnova partners from Luxembourg, Denmark and Germany met to discuss the feedback and recommendations from the advisory board, and to sharpen the project into the final phase of business plan preparation.


Advancing the scientific strategy of Clinnova: second consortium meeting in Heidelberg

Group Picture

On December 14th and 15th the Clinnova Consortium members met at the DKFZ in Heidelberg, Germany, for their second Consortium meeting. The main topics on the agenda were the further definition of the scientific strategy of the Centre of Excellence as well as the organizational model Clinnova could have in the future.

20 participants from the NCT, CIMT, LIH, the University of Luxembourg and FNR were involved in the fruitful discussions to help further cristalize the vision of what Clinnova would look like in the future. Building on existing excellence in Luxembourg in preclinical research and bioinformatics and data analytics, Clinnova will link to the excellence in translational cancer research at DKFZ as well as the expertise of the Odense University hospital of bringing advanced digital tools to patients. Data analytics and integration of data from different sources (clinical, molecular, mobile sensors etc) will be at the core of Clinnva. The clinical focus will be on chronic diseases of the nervous system, in particular multiple sclerosis, as well as on cancers, with a focus on brain and gastrointestinal cancers.

Consortium members also met with representatives of the BioRN Cluster as well as the BioMedX incubator to get inspired by the successful economic valorisation and the development of a prospering biotech ecosystem in the Heidelberg region.


CLINNOVA kick-off meeting brings partners & stakeholders together

Tuesday, 26 September 2017 saw the kick-off meeting for CLINNOVA, for which the project partners, as well as stakeholders from politics, industry and research came together for fruitful discussion about various aspects of CLINNOVA.

DSC_8070 cropped

After an introduction by FNR Secretary General Marc Schiltz, Lydia Mutsch, Luxembourg Minister for Health opened the meeting with a speech touching on the Luxembourgish Government’s diversification strategy, which encompasses the life sciences and healthcare domains, as well as the huge opportunities, especially in the field of digitalisation.

“Indeed the Clinnova project could be a next step in the Luxembourg life sciences and healthcare development and a way into a new era of connecting research and care. This work will without a doubt increase our knowledge and we will certainly identify patterns and make connections we were never able to do in the past.” – Lydia Mutsch, Luxembourg Minister for Health
-Read the whole speech from Lydia Mutsch on the Luxembourg Government website

The meeting progressed with Prof Markus Ollert, Director of the Infection and Immunity Department at the Luxembourg Institute of Health, laying out the vision of the CLINNOVA project.

Prof Markus Ollert from the Luxembourg Institute of Health explains the vision of CLINNOVA

Then it came time for the international partners to present the strengths that have led to their involvement in the CLINNOVA project, beginning with Claus Duedal Pedersen, from the Region of Southern Denmark who spoke about how Denmark’s digital health landscape has evolved and what future challenges are.

Claus Duedahl Pedersen from the Region of Southern Denmark

The final speech before the afternoon group sessions was delivered by Prof Christof von Kalle from Deutsches Krebsforschungszentrum (DKFZ).

Prof Christof von Kalle, Deutsches Krebsforschungszentrum

During the afternoon, the stakeholders were split into smaller groups and asked the following questions:

  • Where do you see the greatest opportunities?
  • What could be ‘showcases’ for Luxembourg?
  • What could be potential stumbling blocks?
  • Who are the key stakeholders?


After one hour to discuss the key questions, each group presented their findings and the meeting culminated in fruitful discussion about various points raised and discussed during the day.